{'fraction_non_alphanumeric': 0.03558282208588957, 'fraction_numerical': 0.0196319018404908, 'mean_word_length': 5.135338345864661, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Heterogeneity of programmed death‐ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences

Thymic epithelial tumors (TET) are rare malignant neoplasms that have the potential to metastasize, recur, or even have a fatal outcome. While many thymomas have a favorable outcome with a 5-year overall survival of 75.8%, reported 5-year survival rates of thymic carcinomas are only 27.5 to 50.5% [1, 2] Complete resection is the curative treatment of choice, however, high stage TET are often not amenable to complete resection. Therefore, alternate treatments such as anti-PD-1/PD-L1 inhibitors, have been studied in this patient population and remain an area of active investigation. This article is protected by copyright. All rights reserved.